Overview

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaverine with chemoradiation may work best to treat patients with non-small cell lung cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Ohio State University Comprehensive Cancer Center

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Carboplatin
Durvalumab
Immunoglobulin G
Immunoglobulins
Paclitaxel
Papaverine